RxDoctor Payments Data

Amanda Foxx, MD

Internal Medicine · Lexington, KYNPI 1639462989

Payments from drug & device makers

$5,207in general payments, 2019–2025

Across 335 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$855
  • AbbVie$810
  • GSK$391
  • Novo Nordisk$361
  • Lilly USA, LLC$351
  • AstraZeneca$244
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$5,14099%
  • Education$220%
  • Other$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,207 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$229,459
Medicare patients
434
Services billed
8,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide88$120,900
JardianceEmpagliflozin85$120,400
EliquisApixaban74$95,236
OzempicSemaglutide63$87,713
TrulicityDulaglutide29$54,416
XareltoRivaroxaban27$39,418
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$34,459
JanuviaSitagliptin Phosphate18$28,899
LinzessLinaclotide13$15,299
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,802
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$11,787
AbrysvoRsv Vacc, Pref A And Pref B/Pf31$9,959
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,122
Tresiba Flextouch U-100Insulin Degludec17$8,336
Repatha SureclickEvolocumab11$8,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$351$175,316117 claims
Boehringer IngelheimJardiance, Stiolto Respimat$104$132,187102 claims
PfizerEliquis, Abrysvo$855$105,195105 claims
Novo NordiskOzempic$361$87,71363 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Shingrix$391$51,69173 claims
Johnson & JohnsonXarelto$50$39,41827 claims
MerckJanuvia$163$28,89918 claims
AbbVieLinzess, Synthroid$810$22,410146 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$244$19,52635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →